Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection

OBJECTIVES: Ridinilazole (SMT19969) is a narrow-spectrum, non-absorbable antimicrobial with activity against Clostridium difficile undergoing clinical trials. The purpose of this study was to assess the pharmacological activity of ridinilazole and assess the effects on cell morphology. METHODS: Anti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Antimicrob Chemother
Hlavní autoři: Bassères, Eugénie, Endres, Bradley T., Khaleduzzaman, Mohammed, Miraftabi, Faranak, Alam, M. Jahangir, Vickers, Richard J., Garey, Kevin W.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2016
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4830417/
https://ncbi.nlm.nih.gov/pubmed/26895772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkv498
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky